Procedur Guideline for Prostate Cancer Imaging: Ga68 PSMA PET/CT

Uçmak, Gülin; Sivrikoz, İlknur Ak; Selçuk, Nalan Alan; Demirci, Emre; Elboğa, Umut; Türkmen, Cüneyt; Kabasakal, Levent

doi:10.4274/nts.galenos.2020.0030

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Radiopharmaceuticals targeting the prostate-specific membrane antigen (PSMA) have seen great success in Nuclear Medicine for both diagnosis and endoradiotherapy of prostate cancer (PCa) [ 1 , 2 ] thus paving the way for (radio)theranostics [ 3 , 4 , 5 ] with guidelines being published by international experts and societies [ 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

Radiolabeled PSMA Inhibitors

Neels

Kopka

Liolios

et al. 2021

Cancers

View full text Add to dashboard Cite

PSMA has shown to be a promising target for diagnosis and therapy (theranostics) of prostate cancer. We have reviewed developments in the field of radio- and fluorescence-guided surgery and targeted photodynamic therapy as well as multitargeting PSMA inhibitors also addressing albumin, GRPr and integrin αvβ3. An overview of the regulatory status of PSMA-targeting radiopharmaceuticals in the USA and Europe is also provided. Technical and quality aspects of PSMA-targeting radiopharmaceuticals are described and new emerging radiolabeling strategies are discussed. Furthermore, insights are given into the production, application and potential of alternatives beyond the commonly used radionuclides for radiolabeling PSMA inhibitors. An additional refinement of radiopharmaceuticals is required in order to further improve dose-limiting factors, such as nephrotoxicity and salivary gland uptake during endoradiotherapy. The improvement of patient treatment achieved by the advantageous combination of radionuclide therapy with alternative therapies is also a special focus of this review.

show abstract